search
Back to results

Supplemental Parenteral Nutrition in Pediatric Respiratory Failure (SuPPeR)

Primary Purpose

Acute Respiratory Failure With Hypoxia, Malnutrition

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Parenteral Nutrition
Sponsored by
University of Arizona
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Respiratory Failure With Hypoxia

Eligibility Criteria

1 Month - 16 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Admitted to study hospital pediatric intensive care unit (PICU),
  2. One month to 16 years of age,
  3. Exhibits Acute Hypoxemic Respiratory Failure as defined as: PaO2/FiO2 ≤ 300 or SpO2/FiO2 ≤ 260, No evidence of cardiac dysfunction, Mechanically ventilated,
  4. Require artificial nutrition,
  5. Anticipate placement of central venous line within 24 hours of admission

Exclusion Criteria:

  1. Premature infants and neonates < 37 weeks corrected gestational age,
  2. Transfer patient on an established enteral or parenteral nutritional regimen,
  3. Known allergy to lactulose or mannitol,
  4. Pregnant,
  5. Admit BMI >30,
  6. Thoracic trauma, abdominal trauma, and/or active intracranial bleeding,
  7. Anuric renal failure, previous bowel surgery and/or short gut syndrome,
  8. Cannot be enterally fed within 24 hours of admission according to the admitting physician,
  9. On extracorporeal membrane oxygenation (ECMO),
  10. Expected survival <24 hours or limitations to aggressive ICU care (DNR),
  11. Receiving active CPR when admitted to the PICU,
  12. A pre-existing bronchopleural fistula,
  13. Previously enrolled and randomized into this protocol,
  14. Actively enrolled in another clinical trial which at the discretion of the PI would conflict with this study.

Sites / Locations

  • University of Arizona Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Early Parenteral Nutrition

Late Parenteral Nutrition

Arm Description

Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.

Patients receive supplemental parenteral nutrition 96 hours after enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.

Outcomes

Primary Outcome Measures

Modified Prognostic Inflammatory and Nutritional Index (PINI)
The change day 0 to day 5 of the modified Prognostic Inflammatory and Nutritional Index (PINI) is a quantitative method to monitor the relation between markers of nutrition and acute phase proteins. It allows assessment of nutrition markers in the context of acute inflammation and in response to early enteral nutrition. A higher baseline PINI score indicates higher degree of inflammation. The modified PINI is calculated by the the ratio of (C-Reactive Protein(mg/dL) x Fibrinogen (mg/dL))/ (Transferrin (mg/dL) x Transthyretin (mg/dL)). The average change in the modified PINI from day 0 to day 5 critically ill children receiving early enteral nutrition is a decrease by 5.3 +/- 3.2 (mean +/- standard error of the mean) (Briassoulis et.al. Nutrition 2001). A larger negative number for the change from day 0 to day 5 indicates a greater degree of inflammation resolution.

Secondary Outcome Measures

Cumulative Percent of Daily Goal Calories Achieved
Evaluate percentage of cumulative goal calories achieved through parenteral and enteral routes in both study arms until patient exits study participation. Measure is calculated by (sum of kcal delivered over days of study participation/number of days in study).
Plasma Intestinal Fatty Acid Binding Protein (I-FABP)
The percent change in plasma Intestinal Fatty Acid Binding Protein from baseline to study day 5, prior to late PN initiation
Plasma Citrulline
Evaluates absolute plasma citrulline concentration as a measure of functional enterocyte mass. A higher citrulline concentration indicates a higher functional enterocyte mass. Healthy children have an average citrulline concentration of 25 +/- 9 uMol/L. Assessed on day 0 and day 5, results reported for day 0 and 5. Outcome analysis on difference between treatment groups on day 5.
Plasma Claudin 3
As a measure of enterocyte tight junctions, calculate the percent change in plasma claudin 3 concentrations from baseline (day 0) and study day 5, prior to late PN administration.
Gastrointestinal Permeability
Gastrointestinal permeability measured with the ratio of urinary recovery of lactulose and mannitol on day 5 of study participation. The range of values is generally reported as 0.02 to 2.2 with a higher value indicating greater gastrointestinal permeability. Values obtained on day 0 and day 5, day 5 reported.

Full Information

First Posted
September 1, 2013
Last Updated
February 11, 2021
Sponsor
University of Arizona
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
search

1. Study Identification

Unique Protocol Identification Number
NCT01937884
Brief Title
Supplemental Parenteral Nutrition in Pediatric Respiratory Failure
Acronym
SuPPeR
Official Title
Supplemental Parenteral Nutrition in Pediatric Respiratory Failure
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Terminated
Why Stopped
Unable to enroll patients
Study Start Date
August 2013 (Actual)
Primary Completion Date
August 2018 (Actual)
Study Completion Date
August 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Arizona
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Optimal delivery of nutritional support during critical illness is central to appropriate intensive care unit management, and yet fundamental gaps in knowledge exist regarding timing, route, dose, and type of nutritional support for critically ill infants and children. Understanding how to optimize nutritional support during pediatric critical illness is important because even brief periods of malnutrition in infancy result in permanent negative effects on long-term neurocognitive development. Optimized nutrition support is a way to improve morbidity for survivors of pediatric critical illness. Parenteral nutrition (PN) supplementation could improve long-term neurocognitive outcome for pediatric critical illness by preventing acute malnutrition, but has unknown effects on intestinal barrier function; a proposed mechanism for late sepsis and infectious complications during critical illness. While randomized controlled trials (RCT) support early PN in premature infants and late PN in critically ill adults, the optimal time to begin PN is unknown for critically ill infants and children. Acute malnutrition may develop within 48 hours of admission in critically ill infants and children, and repleted energy stores are predictive of survival. And yet, due to concerns for PN-associated infectious morbidity, current PICU standard of care is to supplement with PN only in children who fail to enterally feed, as late as 7 days into their admission. Delays in nutrition may have long-term effects on cognitive outcome in older infants and children. In premature infants, PN begun within hours of birth results in improved 18-month neurocognitive outcome without an increase in infectious complications. An RCT is needed to determine if early PN in critically ill infants and children prevents acute malnutrition and improves short and long-term outcomes of PICU hospitalization. The central hypothesis of this proposal is that optimized early protein and calorie delivery will improve nutritional outcomes and intestinal barrier function for critically ill infants and children. The overall purpose of this study is to evaluate the efficacy and safety of early PN as a supplement to enteral nutrition to improve nutritional delivery, nutritional outcomes, and intestinal barrier function for infants and children with acute respiratory failure who are mechanically ventilated in the pediatric intensive care unit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Respiratory Failure With Hypoxia, Malnutrition

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
18 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Early Parenteral Nutrition
Arm Type
Experimental
Arm Description
Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.
Arm Title
Late Parenteral Nutrition
Arm Type
Active Comparator
Arm Description
Patients receive supplemental parenteral nutrition 96 hours after enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.
Intervention Type
Drug
Intervention Name(s)
Parenteral Nutrition
Primary Outcome Measure Information:
Title
Modified Prognostic Inflammatory and Nutritional Index (PINI)
Description
The change day 0 to day 5 of the modified Prognostic Inflammatory and Nutritional Index (PINI) is a quantitative method to monitor the relation between markers of nutrition and acute phase proteins. It allows assessment of nutrition markers in the context of acute inflammation and in response to early enteral nutrition. A higher baseline PINI score indicates higher degree of inflammation. The modified PINI is calculated by the the ratio of (C-Reactive Protein(mg/dL) x Fibrinogen (mg/dL))/ (Transferrin (mg/dL) x Transthyretin (mg/dL)). The average change in the modified PINI from day 0 to day 5 critically ill children receiving early enteral nutrition is a decrease by 5.3 +/- 3.2 (mean +/- standard error of the mean) (Briassoulis et.al. Nutrition 2001). A larger negative number for the change from day 0 to day 5 indicates a greater degree of inflammation resolution.
Time Frame
Change in PINI from day 0 to day 5
Secondary Outcome Measure Information:
Title
Cumulative Percent of Daily Goal Calories Achieved
Description
Evaluate percentage of cumulative goal calories achieved through parenteral and enteral routes in both study arms until patient exits study participation. Measure is calculated by (sum of kcal delivered over days of study participation/number of days in study).
Time Frame
baseline and daily through day 7
Title
Plasma Intestinal Fatty Acid Binding Protein (I-FABP)
Description
The percent change in plasma Intestinal Fatty Acid Binding Protein from baseline to study day 5, prior to late PN initiation
Time Frame
baseline and day 5
Title
Plasma Citrulline
Description
Evaluates absolute plasma citrulline concentration as a measure of functional enterocyte mass. A higher citrulline concentration indicates a higher functional enterocyte mass. Healthy children have an average citrulline concentration of 25 +/- 9 uMol/L. Assessed on day 0 and day 5, results reported for day 0 and 5. Outcome analysis on difference between treatment groups on day 5.
Time Frame
baseline and day 5
Title
Plasma Claudin 3
Description
As a measure of enterocyte tight junctions, calculate the percent change in plasma claudin 3 concentrations from baseline (day 0) and study day 5, prior to late PN administration.
Time Frame
baseline through hour 96
Title
Gastrointestinal Permeability
Description
Gastrointestinal permeability measured with the ratio of urinary recovery of lactulose and mannitol on day 5 of study participation. The range of values is generally reported as 0.02 to 2.2 with a higher value indicating greater gastrointestinal permeability. Values obtained on day 0 and day 5, day 5 reported.
Time Frame
day 5
Other Pre-specified Outcome Measures:
Title
Number of Participants With Hospital-Acquired Infections
Description
Record any hospital-defined hospital acquired infections through day 28 in all study participants.
Time Frame
until hospital discharge or day 28 if still hospitalized
Title
28-day Mortality
Description
Death of a study patient do to any cause measured up to 28 days after study enrollment.
Time Frame
28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Month
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Admitted to study hospital pediatric intensive care unit (PICU), One month to 16 years of age, Exhibits Acute Hypoxemic Respiratory Failure as defined as: PaO2/FiO2 ≤ 300 or SpO2/FiO2 ≤ 260, No evidence of cardiac dysfunction, Mechanically ventilated, Require artificial nutrition, Anticipate placement of central venous line within 24 hours of admission Exclusion Criteria: Premature infants and neonates < 37 weeks corrected gestational age, Transfer patient on an established enteral or parenteral nutritional regimen, Known allergy to lactulose or mannitol, Pregnant, Admit BMI >30, Thoracic trauma, abdominal trauma, and/or active intracranial bleeding, Anuric renal failure, previous bowel surgery and/or short gut syndrome, Cannot be enterally fed within 24 hours of admission according to the admitting physician, On extracorporeal membrane oxygenation (ECMO), Expected survival <24 hours or limitations to aggressive ICU care (DNR), Receiving active CPR when admitted to the PICU, A pre-existing bronchopleural fistula, Previously enrolled and randomized into this protocol, Actively enrolled in another clinical trial which at the discretion of the PI would conflict with this study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Katri V Typpo, MD, MPH
Organizational Affiliation
University of Arizona
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Arizona Medical Center
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85724-5073
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Supplemental Parenteral Nutrition in Pediatric Respiratory Failure

We'll reach out to this number within 24 hrs